CY1123371T1 - Egfr-κατευθυνομενος διπλο-κλωνου rna φορεας για συστημικη θεραπεια καρκινου - Google Patents

Egfr-κατευθυνομενος διπλο-κλωνου rna φορεας για συστημικη θεραπεια καρκινου

Info

Publication number
CY1123371T1
CY1123371T1 CY20191101340T CY191101340T CY1123371T1 CY 1123371 T1 CY1123371 T1 CY 1123371T1 CY 20191101340 T CY20191101340 T CY 20191101340T CY 191101340 T CY191101340 T CY 191101340T CY 1123371 T1 CY1123371 T1 CY 1123371T1
Authority
CY
Cyprus
Prior art keywords
egfr
cancer therapy
carrier rna
directed double
systemic cancer
Prior art date
Application number
CY20191101340T
Other languages
English (en)
Inventor
Alexander Levitzki
Alexei Shir
Original Assignee
Targimmune Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targimmune Therapeutics Ag filed Critical Targimmune Therapeutics Ag
Publication of CY1123371T1 publication Critical patent/CY1123371T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Information Transfer Between Computers (AREA)

Abstract

Φορέας που κατευθύνεται σε υποδοχέα επιδερμικού αυξητικού παράγοντα (EGFR) που περιλαμβάνει διπλόκλωνου RNA (dsRNA) μόριο με πεπτίδιο ή πολυπεπτίδιο σύνδεσης EGFR αποκαλύπτεται για χρήση σε συνδυασμό με άνοσα κύτταρα για θεραπεία καρκίνου που υπερεκφράζει EGFR.
CY20191101340T 2008-12-22 2019-12-20 Egfr-κατευθυνομενος διπλο-κλωνου rna φορεας για συστημικη θεραπεια καρκινου CY1123371T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13969808P 2008-12-22 2008-12-22
PCT/IL2009/001210 WO2010073247A2 (en) 2008-12-22 2009-12-22 Egfr-homing double-stranded rna vector for systemic cancer treatment
EP09806144.3A EP2379597B8 (en) 2008-12-22 2009-12-22 Egfr-homing double-stranded rna vector for systemic cancer treatment

Publications (1)

Publication Number Publication Date
CY1123371T1 true CY1123371T1 (el) 2021-10-29

Family

ID=42104511

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101340T CY1123371T1 (el) 2008-12-22 2019-12-20 Egfr-κατευθυνομενος διπλο-κλωνου rna φορεας για συστημικη θεραπεια καρκινου

Country Status (19)

Country Link
US (2) US9006406B2 (el)
EP (3) EP3098239B1 (el)
JP (1) JP2012513210A (el)
CN (1) CN102325794A (el)
AU (1) AU2009332522A1 (el)
BR (1) BRPI0922985A2 (el)
CA (1) CA2748125A1 (el)
CY (1) CY1123371T1 (el)
DK (2) DK2379597T3 (el)
ES (2) ES2764396T3 (el)
HR (1) HRP20192317T1 (el)
HU (1) HUE047759T2 (el)
IL (1) IL213739A0 (el)
LT (1) LT3098239T (el)
MX (1) MX2011006720A (el)
PL (1) PL3098239T3 (el)
PT (1) PT3098239T (el)
SI (1) SI3098239T1 (el)
WO (1) WO2010073247A2 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164380A1 (en) 2012-05-03 2013-11-07 Janssen R&D Ireland Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
JP6103832B2 (ja) 2012-06-25 2017-03-29 Hoya株式会社 Ｅｇｆｒ結合性ペプチド
US9431064B2 (en) * 2012-11-02 2016-08-30 Taiwan Semiconductor Manufacturing Company, Ltd. Memory circuit and cache circuit configuration
US10796320B2 (en) * 2013-12-23 2020-10-06 Mastercard International Incorporated Systems and methods for passively determining a ratio of purchasers and prospective purchasers in a merchant location
SG10201911695SA (en) * 2014-05-14 2020-01-30 Targimmune Therapeutics Ag Improved polyethyleneimine polyethyleneglycol vectors
WO2016154807A1 (en) * 2015-03-27 2016-10-06 Intel Corporation Dynamic cache allocation
CA3005492C (en) * 2015-11-17 2023-01-10 Bioncotech Therapeutics Sl Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
GB201601868D0 (en) * 2016-02-02 2016-03-16 Lytix Biopharma As Methods
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药（苏州）股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
CN109790225B (zh) * 2016-09-04 2022-09-09 塔尔格免疫治疗有限公司 用于靶向dsRNA的嵌合蛋白
CA3063805C (en) * 2017-05-17 2024-01-09 Bioncotech Therapeutics Sl Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
CN111164093A (zh) * 2017-09-27 2020-05-15 塔尔格免疫治疗有限公司 去势抵抗性前列腺癌
EP3946450A1 (en) * 2019-04-03 2022-02-09 TargImmune Therapeutics AG Immunotherapy for the treatment of cancer
WO2020263770A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Nucleic acid compositions including a polyalkyleneimine-alkoxylene polymer and methods of making and using the same
WO2020263776A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Nucleic acid compositions including a polyalkyleneimine-alkoxylene polymer and methods of making and using the same
US10915418B1 (en) * 2019-08-29 2021-02-09 Snowflake Inc. Automated query retry in a database environment
WO2024100044A1 (en) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003279509A1 (en) 2002-11-18 2004-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Targeted double stranded rna mediated cell killing
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7937291B2 (en) * 2009-04-22 2011-05-03 Visa U.S.A. Inc. Providing an announcement about transactions of a target merchant to a consumer

Also Published As

Publication number Publication date
MX2011006720A (es) 2011-10-06
EP2379597A2 (en) 2011-10-26
ES2602753T3 (es) 2017-02-22
SI3098239T1 (sl) 2020-03-31
HRP20192317T1 (hr) 2020-03-20
BRPI0922985A2 (pt) 2016-10-04
US20120330998A1 (en) 2012-12-27
PT3098239T (pt) 2020-01-15
EP2379597B8 (en) 2016-11-30
HUE047759T2 (hu) 2020-05-28
ES2764396T3 (es) 2020-06-03
EP3098239B1 (en) 2019-10-23
JP2012513210A (ja) 2012-06-14
EP2379597B1 (en) 2016-08-10
CA2748125A1 (en) 2010-07-01
US9006406B2 (en) 2015-04-14
WO2010073247A2 (en) 2010-07-01
US20120021006A1 (en) 2012-01-26
DK2379597T3 (en) 2016-12-05
EP3705493A1 (en) 2020-09-09
IL213739A0 (en) 2011-07-31
AU2009332522A1 (en) 2011-08-11
LT3098239T (lt) 2020-02-10
DK3098239T3 (da) 2020-01-20
EP3098239A1 (en) 2016-11-30
PL3098239T3 (pl) 2020-04-30
WO2010073247A3 (en) 2010-08-19
CN102325794A (zh) 2012-01-18

Similar Documents

Publication Publication Date Title
CY1123371T1 (el) Egfr-κατευθυνομενος διπλο-κλωνου rna φορεας για συστημικη θεραπεια καρκινου
CY1117445T1 (el) Παραγωγα φωσφοραμιδικου της 5-φθορο-2´-δεοξυουριδινης για χρηση στην θεραπεια καρκινου
CY1121198T1 (el) Αντινοημaτικα μορια και μεθοδοι για την θεραπεια παθολογιων
CY1122664T1 (el) Θεραπεια για την προωθηση κυτταρικης αναπτυξης
CY1121913T1 (el) Αντισωματα αντιδραστικα me b7-h3, ανοσολογικα δραστικα θραυσματα τους και χρησεις τους
CY1121185T1 (el) Αδενοϊος που εκφραζει fas-χιμαιρα και χρηση αυτης σε μεθοδους θεραπειας καρκινου
EA201791843A2 (ru) Способы повышения эффективности folr1 терапии рака
CY1123010T1 (el) Διεγερση γονιδιου τrail με μικρο μοριο απο κανονικα και ογκου κυτταρα ως αντικαρκινικη θεραπεια
CY1121038T1 (el) Θεραπεια καρκινου μαστου
TR201904022T4 (tr) Konakçı hücre modifikasyon yöntemleri.
CY1124849T1 (el) Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων
MX2021009190A (es) Conjugados de penetracion celular y metodos de uso de estos.
CY1114483T1 (el) Νεα ρυθμιστικα στοιχεια
CY1120136T1 (el) Μεθοδος για την αυξηση της ανοσοδραστικοτητας
TR201905909T4 (tr) Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
UA111711C2 (uk) Засіб імунотерапії деяких видів пухлин, у тому числі раку шлунково-кишкового тракту і раку шлунка
MX350082B (es) Moleculas de entrega selectiva y metodos de uso.
MX2014006182A (es) Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr.
TR201909747T4 (tr) Aktarım.
MX2010008496A (es) Metodo para la determinacion de sensibilidad a agente anticancerigeno.
CY1121244T1 (el) Συνδυασμος αναστολεα τελομερασης και γεμσιταβινής για τη θεραπεια του καρκινου
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
CY1117000T1 (el) Ενζυματικη αντικαρκινικη θεραπεια
BR112015008381A2 (pt) aquecedor portátil ativado por oxigênio com almofada de eletrólito
EA201171244A1 (ru) Способы лечения видов рака антисмысловыми олигонуклеотидами her3